Last reviewed · How we verify
Novodigal (acetyldigoxin)
Novodigal (generic name: acetyldigoxin) is a acetyldigoxin drug. It is currently in unknown development.
Novodigal works by inhibiting the sodium-potassium ATPase pump in cardiac cells, leading to increased contractility and a stronger heartbeat.
Novodigal, also known as α-Acetyldigoxin, is a small molecule cardiac glycoside. It is being studied as a therapeutic vaccine candidate in a Phase I clinical trial for the treatment of localized breast cancer at high-risk of relapse.
At a glance
| Generic name | acetyldigoxin |
|---|---|
| Drug class | acetyldigoxin |
| Therapeutic area | Cardiovascular |
| Phase | unknown |
Mechanism of action
Imagine your heart cells are like muscles that need to contract to pump blood. Novodigal helps these muscles contract more strongly by blocking a pump that normally helps them relax. This makes the heart beat stronger and more efficiently.
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Novodigal CI brief — competitive landscape report
- Novodigal updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Novodigal
What is Novodigal?
How does Novodigal work?
What is the generic name of Novodigal?
What drug class is Novodigal in?
What development phase is Novodigal in?
Related
- Drug class: All acetyldigoxin drugs
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Cardiovascular
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing